期刊
NATURE REVIEWS DRUG DISCOVERY
卷 6, 期 11, 页码 904-916出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2423
关键词
-
资金
- NCRR NIH HHS [K24RR02815, K24 RR020815-05, K24 RR020815] Funding Source: Medline
- NHLBI NIH HHS [U01 HL069757, HL 69757, U01 HL65962, U01 HL065962-08, U01 HL065962, U19 HL069757, U01 HL069757-08] Funding Source: Medline
- NIDDK NIH HHS [U01 DK065201, U01 DK065201-05] Funding Source: Medline
- NIGMS NIH HHS [U01 GM074492, U01 GM061373, U01 GM061373-10, U01 GM074492-04, U01 GM061390, TR2GM008425, T32 GM008425, GM61390, U19 GM061390] Funding Source: Medline
Serious adverse drug reactions (SADRs) are a major cause of morbidity and mortality worldwide. Some SADRs may be predictable, based upon a drug's pharmacodynamic and pharmacokinetic properties. Many, however, appear to be idiosyncratic. Genetic factors may underlie susceptibility to SADRs and the identification of predisposing genotypes may improve patient management through the prospective selection of appropriate candidates. Here we discuss three specific SADRs with an emphasis on genetic risk factors. These SADRs, selected based on widesweeping clinical interest, are drug-induced liver injury, statin-induced myotoxicity and drug-induced long QT and torsades de pointes. Key challenges for the discovery of predictive risk alleles for these SADRs are also considered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据